重新评估病理完全缓解作为人表皮生长因子受体2阳性早期乳腺癌新辅助治疗(含抗人表皮生长因子受体2治疗)中无事件生存期和总生存期替代终点的价值
该研究利用11项随机试验的3980例患者个体数据,中位随访62个月,分析病理完全缓解(pCR,定义为ypT0/Tis ypN0)与无事件生存期(EFS)和总生存期(OS)的关联。患者水平关联强(EFS的OR为2.64,OS的OR为3.15),但试验水平关联弱(EFS的R²为0.23,OS的R²为0.02)。结论认为pCR不能作为EFS或OS的替代终点。
要点
- 患者水平上,达到pCR与EFS改善相关(OR 2.64,95%CI 2.20-3.07)。
- 患者水平上,达到pCR与OS改善相关(OR 3.15,95%CI 2.38-3.91)。
- 试验水平上,pCR治疗效应与EFS(R²=0.23)和OS(R²=0.02)关联弱。
核心结论
- pCR可能有助于患者管理,但在HER2阳性可手术乳腺癌的新辅助试验中不能被视为EFS或OS的替代终点。
研究设计与样本
- 研究获取了纳入至少100例患者、具有pCR、EFS和OS数据且中位随访至少3年的随机新辅助抗HER2治疗试验的个体患者数据。
- 15项符合条件试验中的11项有数据可供分析,共3980例患者,中位随访62个月。
主要发现
- 所有试验汇总分析显示患者水平关联强:pCR与EFS的OR为2.64(95%CI 2.20至3.07),与OS的OR为3.15(95%CI 2.38至3.91)。
- 试验水平关联弱:未调整的R²对于EFS为0.23(95%CI 0至0.66),对于OS为0.02(95%CI 0至0.17)。
- 按不同临床问题分组试验、仅分析激素受体阴性病患者或使用更严格pCR定义(ypT0 ypN0)时,结果定性相似。
关键数值与推荐
- pCR定义为ypT0/Tis ypN0。
- OR大于1.00表示达到pCR带来获益。
- R²值大于0.75被认为表示强关联。
临床怎么用
- 作者认为pCR可能有助于患者管理,但不能作为EFS或OS的替代终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate for event-free survival (EFS) and overall survival (OS) in human epidermal growth factor receptor 2 (HER2)-positive, early breast cancer. METHODS: We obtained individual-patient data from randomized trials of neoadjuvant anti-HER2 therapy that enrolled at least 100 patients, had data for pCR, EFS, and OS, and a median follow-up of at least 3 years. We quantified the patient-level association between pCR (defined as ypT0/Tis ypN0) and both EFS and OS using odds ratios (ORs, with ORs >1.00 indicating a benefit from achieving a pCR). We quantified the trial-level association between treatment effects on pCR and on EFS and OS using R2 (with values above 0.75 considered as indicating strong associations). RESULTS: Eleven of 15 eligible trials had data for analysis (3,980 patients, with a median follow-up of 62 months). Considering all trials, we found strong patient-level associations, with ORs of 2.64 (95% CI, 2.20 to 3.07) for EFS and 3.15 (95% CI, 2.38 to 3.91) for OS; however, trial-level associations were weak, with an unadjusted R2 of 0.23 (95% CI, 0 to 0.66) for EFS and 0.02 (95% CI, 0 to 0.17) for OS. We found qualitatively similar results when grouping trials according to different clinical questions, when analyzing only patients with hormone receptor-negative disease, and when using a more stringent definition of pCR (ypT0 ypN0). CONCLUSION: Although pCR may be useful for patient management, it cannot be considered as a surrogate for EFS or OS in neoadjuvant trials of HER2-positive, operable breast cancer.
引用
- Squifflet P, Saad ED, Loibl S, et al. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. J Clin Oncol. 2023. PMID: 36977286. doi:10.1200/JCO.22.02363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。